17AAG treatment improves survival and decreases seizures in Tsc1^GFAPCKO mice. (A) The survival rate revealed that 50% of the DMSO-treated Tsc1^GFAPCKO mice died by 6 wk of age, and all died by ∼12 wk of age. In contrast, 17AAG treatment significantly increased the survival rate of the Tsc1^GFAPCKO mice (P = 0.0146, Kaplan-Meier log-rank test). Cumulative data from two individual experiments with 13 DMSO-treated mice and 14 17AAG-treated mice pooled per experiment. (B) Statistical analysis of the total number of seizures in 6–7 wk of age (n = 6 mice per group, *, P < 0.05; **, P < 0.01, Student’s t test). Data are representative of two independent experiments. (C) Schematic representation of Hsp90β-mediated GLT-1 degradation and the anticonvulsant effect of 17AAG.